Infectious disease pharmaceutical company Poolbeg Pharma updated the market on its intellectual property (IP) position around ‘POLB 001’ on Tuesday, which it described as a small molecule immunomodulator for the treatment of

Poolbeg Pharma has been granted patents by the US Patent and Trademark Office (USPTO) for POLB 001, a small molecule immunomodulator for the treatment of severe influenza and POLB 002,

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost

Poolbeg Pharma said on Tuesday that the US Patent and Trademarks Office has indicated that it is likely to accept the company’s application to expand its intellectual property protections around

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost

While COVID-19 remains a top research priority globally for government and nonprofit entities in partnership with biopharma companies, deal activity also is heavily focused on other infectious diseases, such as

As global temperatures have gone up, so too have outbreaks of many infectious illnesses. Climate change has exacerbated 218 out of 375 conditions Climate change is constantly in the news